Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at the colourful history of one of the biggest drugmakers in the world. Pfizer was founded in 1849 by two recent ...

Pfizer is advancing on a broad front in its ... Before that, it dropped the development of another oral GLP-1 called lotiglipron, after finding a signal that it may cause liver toxicity in some ...

Merck is battling selling pressure, but strong analyst targets suggest upside potential. Pfizer faces a bearish trend with minimal upside, though analysts expect a moderate gain. Get two weeks of ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday ...

Pfizer acquired Biohaven for $11.6bn in October 2022 based on a strong sales forecast for Nurtec ODT. Image credit: Shutterstock/Molly Woodward. Pfizer has agreed to pay $59.7m to resolve illegal ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

Pfizer (NYSE:PFE) just dropped some big news, and it's a game-changer for cancer treatment. The company announced top-tier results from its Phase 3 BREAKWATER trial of BRAFTOVI (encorafenib) in ...